The Sunshine Reporter

The Candidemia Market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medical development.

The Candidemia Market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Candidemia Market size. The report also covers current pancreatic cancer treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key takeaways from the Candidemia Market Research Report

• The current understanding of Candidemia has greatly improved in recent decades, leading to innovative antifungal drugs, growing awareness, improved management, and better outcomes.
• According to DelveInsight’s analysis, Candidemia is slightly more prominent in males in comparison to females.
• The Candidemia market is expected to grow due to factors like an increase in the patient pool and the expected launch of novel emerging therapies
• Candidemia Market Companies are working such as Amplyx Pharmaceuticals, Cidara Therapeutics Inc., Scynexis, Inc., and others.
• Candidemia Pipeline Therapies such as ERAXIS (anidulafungin), Fosmanogepix, Rezafungin (CD101), and others.

Discover more about therapies set to grab major Candidemia market research report @ Candidemia Market Size

Candidemia Overview

Candidemia is a serious, life-threatening bloodstream infection and possibly the fourth most common all-type bloodstream infection seen in the intensive care unit setting. The incidence of Candida bloodstream infection is bimodal, with the elderly and very young having the highest risk of any population suffering from this disease. Invasive fungal infections in critically ill patients are associated with considerable morbidity and mortality. Candida and Aspergillus species are the most frequent causes of healthcare-associated fungal infections in these patients. Although Candida infections are the most frequent fungal infections in ICU patients, invasive aspergillosis is associated with higher morbidity and mortality rates, even in the absence of traditional hematological risk factors. Occasionally, cryptococcosis, pneumocystosis, or zygomycosis may also be encountered in the ICU setting in patients with solid organ or hematopoietic stem cell transplantation, acquired immunodeficiency syndrome, cancer, or hematological malignancies.

Candidemia Epidemiology Segmentation in the 7MM

• Total Candidemia Incident cases
• Candidemia Age-specific cases
• Candidemia Gender-specific cases
• Total patients receiving antifungal treatment

Download the report to understand which factors are driving Candidemia market trends @ Candidemia Market Outlook

Candidemia Market Insights

The term candidemia describes the presence of Candida infection in the blood. Candidemia is the most common manifestations of invasive candidiasis. Candida in a blood culture should never be viewed as a contaminant and should always prompt a search for the source of the bloodstream infection. For many patients, candidemia is a manifestation of invasive candidiasis that could have originated in a variety of organs, whereas for few, candidemia originated from an infected indwelling intravenous catheter. As candidemia can cause serious, life-threatening illness, treatment is usually begun when an infection is suspected. Treatment includes finding the infection source, and if possible, removing it (for example, the central venous catheter) and beginning treatment with anti-fungal medication.       

Candidemia Treatment Market

The treatments used to manage Candida infections vary substantially. They are based on the anatomic location of the infection, the patients’ underlying disease and immune status, the patients’ risk factors for infection, the specific species of Candida responsible for the infection, and, in some cases, the susceptibility of the Candida species to specific antifungal drugs. The armamentarium of drugs for candidiasis treatment currently comprises three major drug classes: polyenes, azoles, and echinocandins.

Learn more about Candidemia therapies in clinical trials @ Candidemia Market Share      

Scope of the Candidemia Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2022-2032
• CandidemiaCompanies- Amplyx Pharmaceuticals, Cidara Therapeutics Inc., Scynexis, Inc., and others.
• CandidemiaPipeline therapies- ERAXIS (anidulafungin), Fosmanogepix, Rezafungin (CD101), and others
• Therapeutic Assessment: Candidemia current marketed and emerging therapies
• Candidemia Market Dynamics:  Candidemia market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Candidemia Market Access and Reimbursement

Table of Content

1. Key Insights

2. Executive Summary of Candidemia

3. Competitive Intelligence Analysis for Candidemia

4. Candidemia: Market Overview at a Glance

5. Candidemia: Disease Background and Overview

6. Patient Journey

7. Candidemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Candidemia Unmet Needs

10. Key Endpoints of Candidemia Treatment

11. Candidemia Marketed Products

12. Candidemia Emerging Therapies

13. Candidemia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Candidemia Market Outlook

16. Access and Reimbursement Overview of Candidemia

17. KOL Views

18. Candidemia Market Drivers

19. Candidemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/